{
    "id": "db72899c08",
    "abstract": [],
    "body_text": [
        {
            "text": "postpartum (range 6.5-12.9%), and in the past decade the use of SSRIs to treat depression during pregnancy and breast-feeding has increased considerably [2][3][4].",
            "ref_spans": [
                {
                    "start": 153,
                    "end": 156,
                    "type": "bibr",
                    "ref_id": "b1",
                    "text": "[2]"
                },
                {
                    "start": 156,
                    "end": 159,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "[3]"
                },
                {
                    "start": 159,
                    "end": 162,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "[4]"
                }
            ]
        },
        {
            "text": "However, the use of SSRIs during gestation and postpartum may carry risks for the offspring, as these psychoactive drugs can cross the placenta and also pass into breast milk, thus reaching the fetus and infant during critical developmental stages [5,6]. ",
            "ref_spans": [
                {
                    "start": 248,
                    "end": 251,
                    "type": "bibr",
                    "ref_id": "b4",
                    "text": "[5,"
                },
                {
                    "start": 251,
                    "end": 253,
                    "type": "bibr",
                    "ref_id": "b5",
                    "text": "6]"
                }
            ]
        },
        {
            "text": "In humans, studies"
        },
        {
            "text": "Selective serotonin reuptake inhibitors (SSRIs) are antidepressant drugs recommended as first-line pharmacotherapy for unipolar depression [1]. ",
            "section": "Background and aims",
            "ref_spans": [
                {
                    "start": 139,
                    "end": 142,
                    "type": "bibr",
                    "ref_id": "b0",
                    "text": "[1]"
                }
            ]
        },
        {
            "text": "The prevalence of depression is high during pregnancy and regarding perinatal SSRI exposure and adverse outcomes in offspring have focused on risks of fetal malformations, birth weight, respiratory distress, neonatal convulsions and some neurodevelopmental effects such as psychomotor delays, behavioral changes and autism [5,7,8]. ",
            "section": "Background and aims",
            "ref_spans": [
                {
                    "start": 323,
                    "end": 326,
                    "type": "bibr",
                    "ref_id": "b4",
                    "text": "[5,"
                },
                {
                    "start": 326,
                    "end": 328,
                    "type": "bibr",
                    "ref_id": "b6",
                    "text": "7,"
                },
                {
                    "start": 328,
                    "end": 330,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "8]"
                }
            ]
        },
        {
            "text": "Endocrinerelated reproductive effects in children exposed in utero and/or through lactation have not received attention thus far.",
            "section": "Background and aims"
        },
        {
            "text": "Fluoxetine (FLX), a major representative of SSRIs, has been linked to reproductive and/or (neuro) endocrine toxicity in aquatic organisms, rodents and humans [9][10][11]. ",
            "section": "Background and aims",
            "ref_spans": [
                {
                    "start": 158,
                    "end": 161,
                    "type": "bibr",
                    "ref_id": "b8",
                    "text": "[9]"
                },
                {
                    "start": 161,
                    "end": 165,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "[10]"
                },
                {
                    "start": 165,
                    "end": 169,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "[11]"
                }
            ]
        },
        {
            "text": "Studies on fish showed that FLX can disrupt the physiological responses of the reproductive axis by interfering with the neuroendocrine regulation of steroidogenesis and gametogenesis. ",
            "section": "Background and aims"
        },
        {
            "text": "Furthermore, FLX can also disrupt estrogen signaling in the brain by reducing the expression of estrogen receptors in the hypothalamus [10]. ",
            "section": "Background and aims",
            "ref_spans": [
                {
                    "start": 135,
                    "end": 139,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "[10]"
                }
            ]
        },
        {
            "text": "In addition, a few studies on rodents suggested that FLX could interfere with sexual steroid signaling during development, as this compound was able to affect sexual brain differentiation, sexual behaviour, testicular development and sperm production in rat offspring exposed in utero and/or through lactation [12][13][14][15][16]. ",
            "section": "Background and aims",
            "ref_spans": [
                {
                    "start": 310,
                    "end": 314,
                    "type": "bibr",
                    "ref_id": "b11",
                    "text": "[12]"
                },
                {
                    "start": 314,
                    "end": 318,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "[13]"
                },
                {
                    "start": 318,
                    "end": 322,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "[14]"
                },
                {
                    "start": 322,
                    "end": 326,
                    "type": "bibr",
                    "ref_id": "b14",
                    "text": "[15]"
                },
                {
                    "start": 326,
                    "end": 330,
                    "type": "bibr",
                    "ref_id": "b15",
                    "text": "[16]"
                }
            ]
        },
        {
            "text": "Finally, a study by Mueller et al. showed that FLX can activate estrogen receptors in vitro and can also induce an estrogendependent uterotrophic response in rodents [17].",
            "section": "Background and aims",
            "ref_spans": [
                {
                    "start": 166,
                    "end": 170,
                    "type": "bibr",
                    "ref_id": "b16",
                    "text": "[17]"
                }
            ]
        },
        {
            "text": "In vivo, fluoxetine is metabolized to norfluoxetine (NFLX), an active molecule for which there is no published data regarding its endocrine effects [18]. ",
            "section": "Background and aims",
            "ref_spans": [
                {
                    "start": 148,
                    "end": 152,
                    "type": "bibr",
                    "ref_id": "b17",
                    "text": "[18]"
                }
            ]
        },
        {
            "text": "Consequently, this study aimed at assessing the capacity of NFLX to elicit estrogenic or antiestrogenic effects in vitro, using a firefly luciferase-reporter assay in an estrogen receptor (ER) positive cell line. ",
            "section": "Background and aims"
        },
        {
            "text": "Stock solutions NFLX and E 2 were prepared as stock solutions in dimethyl sulfoxide (DMSO, Riedel-de Ha\u00ebn, Seelze, Germany). ",
            "section": "Background and aims"
        },
        {
            "text": "Subsequent serial dilutions were prepared and then used to obtain the desired test concentration range for NFLX and E 2 .",
            "section": "Background and aims"
        },
        {
            "text": "Cell culture Estrogen receptor positive T47D-KBluc human breast cancer cells were obtained from American Type Culture Collection (ATCC, USA). ",
            "section": "Chemicals and reagents"
        },
        {
            "text": "The cells were maintained in 75 cm 2 flasks with RPMI1640 + GlutaMAX medium, supplemented with 10% FBS at 37\u00b0C in an atmosphere of 5% CO 2 , under saturating humidity. ",
            "section": "Chemicals and reagents"
        },
        {
            "text": "During every cell passage the cells were rinsed with PBS and were detached from plastic flasks using trypsin.",
            "section": "Chemicals and reagents"
        },
        {
            "text": "Cell viability assay Cell viability was evaluated using a resazurinbased assay. ",
            "section": "Chemicals and reagents"
        },
        {
            "text": "For this test, T47D-KBluc cells were seeded at 5x10 5 cells/mL (96 wells/plate) in RPMI1640 with GlutaMAX medium. ",
            "section": "Chemicals and reagents"
        },
        {
            "text": "Following a 24h incubation at 37\u00b0C, 5% CO 2 , the cells were rinsed with 200 \u00b5L PBS and then exposed for 24h to NFLX in increasing concentrations or binary mixtures of NFLX in increasing concentrations and 30 pM E 2 (the lowest E 2 concentration that induced a maximum response in this cell line). ",
            "section": "Chemicals and reagents"
        },
        {
            "text": "The experiments were performed in triplicate. ",
            "section": "Chemicals and reagents"
        },
        {
            "text": "Viable cells are able to reduce the non-fluorescent resazurin reagent to a fluorescent product called resorufin. ",
            "section": "Chemicals and reagents"
        },
        {
            "text": "After exposure to test compounds or mixtures, the cells were rinsed with 200\u00b5L PBS and then incubated with 200 \u00b5L of a 100 \u00b5M resazurin solution, for 3h at 37\u00b0C, 5% CO 2 . ",
            "section": "Chemicals and reagents"
        },
        {
            "text": "Using a plate-reader (Synergy 2 Multi-Mode Microplate Reader, BioTek), the fluorescence of resorufin in viable cells was measured at \u03bb excitation =530/25; \u03bb emission =590/35.",
            "section": "Chemicals and reagents",
            "entity_spans": [
                {
                    "type": "software",
                    "start": 22,
                    "end": 29,
                    "rawForm": "Synergy",
                    "resp": "whitelist",
                    "id": "db72899c08-software-simple-w0"
                }
            ]
        },
        {
            "text": "Experiments were performed three times in triplicate. ",
            "section": "Luciferase assay"
        },
        {
            "text": "Data was expressed either as percentages of nontreated controls (individual testing) or as percentages of the signal observed for 30 pM E 2 (testing mixtures NFLX-E 2 ). ",
            "section": "Luciferase assay"
        },
        {
            "text": "The normality of the distribution of data was tested with the Shapiro-Wilk test (p<0.05). ",
            "section": "Luciferase assay"
        },
        {
            "text": "To compare data, 1-way ANOVA was applied to normally distributed data, followed by Dunnett's Multiple Comparison post hoc test. ",
            "section": "Luciferase assay"
        },
        {
            "text": "For data that were not normally distributed we used KruskalWallis test, followed by Dunnett's Multiple Comparison test. ",
            "section": "Luciferase assay"
        },
        {
            "text": "Differences in P values of <0.05 were considered statistically significant. ",
            "section": "Luciferase assay"
        },
        {
            "text": "All statistical analyses and graphs were performed using GraphPad Prism 5.",
            "section": "Luciferase assay",
            "entity_spans": [
                {
                    "start": 57,
                    "end": 65,
                    "type": "publisher",
                    "rawForm": "GraphPad",
                    "resp": "#curator",
                    "id": "#db72899c08-software-0"
                },
                {
                    "start": 66,
                    "end": 71,
                    "type": "software",
                    "rawForm": "Prism",
                    "resp": "#annotator2",
                    "used": true,
                    "id": "db72899c08-software-0",
                    "cert": "0.8"
                },
                {
                    "start": 72,
                    "end": 73,
                    "type": "version",
                    "rawForm": "5",
                    "resp": "#annotator2",
                    "id": "#db72899c08-software-0"
                },
                {
                    "type": "software",
                    "start": 57,
                    "end": 65,
                    "rawForm": "GraphPad",
                    "resp": "whitelist",
                    "id": "db72899c08-software-simple-w1"
                }
            ]
        },
        {
            "text": "To assess cell viability in the presence of NFLX, T47D-Kbluc cells were exposed to NFLX in increasing concentrations (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 15 and 20 \u00b5M) for 24 hours. ",
            "section": "Cell viability assay"
        },
        {
            "text": "NFLX significantly decreased cell viability at 15 and 20 \u00b5M (data not shown) and therefore, these concentrations were excluded from further testing. ",
            "section": "Cell viability assay"
        },
        {
            "text": "Mixtures NFLX (increasing concentrations as stated above) and E 2 (constant concentration 30 pM) were also evaluated using the same assay and incubation time. ",
            "section": "Cell viability assay"
        },
        {
            "text": "Again, mixtures that contained NFLX in concentrations above 10 \u00b5M significantly decreased cell viability (data not shown) and were excluded from further testing.",
            "section": "Cell viability assay"
        },
        {
            "text": "To test for estrogenic effects of NFLX, T47D-Kbluc cells were incubated with increasing concentrations of NFLX (0.01, 0.03, 0.1, 0.3, 1, 3 and 10\u00b5M) for 24 hours. ",
            "section": "Luciferase assay"
        },
        {
            "text": "A significant increase in luciferase activity as compared to control was observed only at the highest concentration tested, 10 \u00b5M (Figure 1). ",
            "section": "Luciferase assay",
            "ref_spans": [
                {
                    "start": 130,
                    "end": 139,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "(Figure 1"
                }
            ]
        },
        {
            "text": "This induction represents 10% of the E 2 response at 30 pM in T47D-Kbluc cells.",
            "section": "Luciferase assay"
        },
        {
            "text": "At low concentrations, mixtures NFLX (increasing concentrations as mentioned above) and E 2 (constant concentration 30 pM) yielded a significant increase in luciferase activity as compared to E 2 , whereas the highest concentration tested induced a significant decrease in luciferase activity (Figure 2).",
            "section": "Luciferase assay",
            "ref_spans": [
                {
                    "start": 293,
                    "end": 302,
                    "type": "figure",
                    "ref_id": "fig_3",
                    "text": "(Figure 2"
                }
            ]
        },
        {
            "text": "In the light of the recent findings on FLX interactions with the nuclear estrogenic receptors (ERs), we aimed at assessing if the main metabolite, NFLX, shares the same capacity to interfere with estrogenic signaling [17]. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 217,
                    "end": 221,
                    "type": "bibr",
                    "ref_id": "b16",
                    "text": "[17]"
                }
            ]
        },
        {
            "text": "As the parent compound, NFLX is highly lipophilic and crosses the blood-brain barrier to accumulate in the brain, where it acts as an antidepressant by selectively blocking the serotonin transporter [18]. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 199,
                    "end": 203,
                    "type": "bibr",
                    "ref_id": "b17",
                    "text": "[18]"
                }
            ]
        },
        {
            "text": "However, the structural and functional similarities of the two compounds suggest that NFLX might also be an active ligand for nuclear ERs.",
            "section": "Discussion"
        },
        {
            "text": "Indeed, the results of the in vitro firefly-luciferase assay show that NFLX alone can induce estrogenic effects by activating the nuclear estrogenic receptors and thus affecting the ER-regulated gene expression. ",
            "section": "Discussion"
        },
        {
            "text": "However,  the small magnitude of the observed effect (10% of E 2 induction) suggests that NFLX is a weak ER agonist at high concentrations.",
            "section": "Discussion"
        },
        {
            "text": "We further tested mixtures of NFLX and E 2 to simulate the biological scenario where this compound would be present at the ERs alongside their natural ligand. ",
            "section": "Discussion"
        },
        {
            "text": "In this case, NFLX caused an increase in the E 2induced transcriptional activity at low (submicromolar) concentrations. ",
            "section": "Discussion"
        },
        {
            "text": "Considering the fact that no effect was observed at these concentrations during individual testing, we hypothesize that NFLX can act in a synergistic manner with E 2 . ",
            "section": "Discussion"
        },
        {
            "text": "Conversely, at 10 \u03bcM we observed a significant decrease in signal as compared to E 2 . ",
            "section": "Discussion"
        },
        {
            "text": "This is in line with the previous finding from individual testing and suggests that NFLX can displace the natural ligand from the ERs, thus resulting in a decrease in signal due to the weak agonist properties of NFLX.",
            "section": "Discussion"
        },
        {
            "text": "These results may raise concern regarding the endocrine disruptive potential of NFLX, since the synergistic effect observed at submicromolar concentrations suggests that this compound may interfere with estrogenic signaling at therapeutic plasma concentrations, which are reported to be below 1 \u03bcM, with variations depending on FLX dose and CYP2D6/CYP2C9 genotype [19,20]. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 364,
                    "end": 368,
                    "type": "bibr",
                    "ref_id": "b18",
                    "text": "[19,"
                },
                {
                    "start": 368,
                    "end": 371,
                    "type": "bibr",
                    "ref_id": "b19",
                    "text": "20]"
                }
            ]
        },
        {
            "text": "In the fetus and newborns, NFLX concentrations reach aproximately 70 to 80% of the maternal plasma levels [21]. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 106,
                    "end": 110,
                    "type": "bibr",
                    "ref_id": "b20",
                    "text": "[21]"
                }
            ]
        },
        {
            "text": "Also, during breastfeeding, the infants receive less than 1% of the maternal FLX dose through breast milk [21]. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 106,
                    "end": 110,
                    "type": "bibr",
                    "ref_id": "b20",
                    "text": "[21]"
                }
            ]
        },
        {
            "text": "However, FLX, as well as NFLX are highly bound to plasma proteins (~95%) and therefore less compound may be available for receptor interaction in vivo compared to our in vitro studies [22,23]. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 184,
                    "end": 188,
                    "type": "bibr",
                    "ref_id": "b21",
                    "text": "[22,"
                },
                {
                    "start": 188,
                    "end": 191,
                    "type": "bibr",
                    "ref_id": "b22",
                    "text": "23]"
                }
            ]
        },
        {
            "text": "Little is known about the level of FLX or NFLX protein binding and metabolism in the fetus and newborn [24]. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 103,
                    "end": 107,
                    "type": "bibr",
                    "ref_id": "b23",
                    "text": "[24]"
                }
            ]
        },
        {
            "text": "Although higher concentrations can be achieved in brain tissue due to accumulation of FLX and NFLX, the biological significance of the observed effect of NFLX at 10 \u03bcM remains unclear due to the fact that only total FLX-NFLX concentrations have been reported for the human brain (~ 13 \u03bcM) [25]. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 289,
                    "end": 293,
                    "type": "bibr",
                    "ref_id": "b24",
                    "text": "[25]"
                }
            ]
        },
        {
            "text": "Further in vitro and in vivo testing would be useful to understand the relevance of our present findings in the context of disrupted estrogenic signaling during development.",
            "section": "Discussion"
        },
        {
            "text": "A limitation of the present study lies in the fact that the observed interaction with the nuclear ERs was not confirmed through tests in the presence of total ER antagonists.",
            "section": "Discussion"
        },
        {
            "text": "In conclusion, this is the first study to report that NFLX has the potential to interfere with estrogenic signaling in vitro, either by increasing or decreasing the ER-mediated activity of 17\u03b2-estradiol.",
            "section": "Conclusion"
        },
        {
            "text": "This paper was published under the frame of European Social Found, Human Resources Development Operational Programme 2007-2013, project no. ",
            "section": "Acknowledgement"
        },
        {
            "text": "POSDRU/159/1.5/136893.",
            "section": "Acknowledgement"
        }
    ]
}